Apogee Therapeutics, Inc.
APGE
Peringkat dalam Saham
#2337
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Harga Saham
$135.07
Terakhir disinkronkan: 2026-09-04
Kapitalisasi Pasar
$8.36B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
152.56%
Negara
US
Perdagangan Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
Riwayat harga saham Apogee Therapeutics, Inc. (APGE)
Harga penutupan tertinggi: $135.07 pada 2026-09-01
Harga penutupan terendah: $20.79 pada 2023-07-01
Harga penutupan terendah: $20.79 pada 2023-07-01
Riwayat harga saham Apogee Therapeutics, Inc. dari 2023 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | 17.47% |
| 2025 | 60.85% |
| 2024 | 96.41% |
| 2023 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
